Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(21)
•••
Post by StockHawk1on Sep 12, 2022 4:48pm
131 Views
Post# 34957807

Breakdown for AGN's latest clinical study approval

Breakdown for AGN's latest clinical study approval

Today Algernon Pharmaceuticals Inc. (AGN.c AGNPF) announced that it has received approval to conduct a Phase 1 clinical study of an IVF of DMT for the treatment of stroke. AGN plans to dose the first subject of the study in Q4.


AGN decided to investigate DMT for ischemic stroke because multiple independent preclinical studies demonstrated that DMT helps mitigate tissue damage and promotes neurogenesis & neural plasticity. 


AGN also found that DMT increased the growth of cortical neurons by up to 40% compared to control in its own pre-clinical study.


The first part of the clinical IVF study will try to identify a safe non-psychedelic dose.


The second part will test the effects of repeated administrations of the non-psychedelic dose. 


More info here:

https://ca.finance.yahoo.com/news/algernon-pharmaceuticals-receives-approval-groundbreaking-110000273.html


AGN @ $6.01

MC $11.924M

 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities